Acute renal failure in patients with cirrhosis: Perspectives in the age of MELD

Hepatology

Volumn 37, Issue 2, 2003, Pages 233-243

  Moreau, Richard ^a   Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CEFOTAXIME; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIURETIC AGENT; DOPAMINE; DROTRECOGIN; FOSCARNET; INSULIN; IODINATED CONTRAST MEDIUM; IRBESARTAN; ISOSORBIDE 5 NITRATE; LOSARTAN; MANNITOL; METHOTREXATE; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OCTREOTIDE; PHENYTOIN; ROFECOXIB; SODIUM CHLORIDE; TACROLIMUS; TERLIPRESSIN; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; FLUID THERAPY; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; INSULIN TREATMENT; INTENSIVE CARE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY TUBULE NECROSIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING; URINALYSIS;

EID: 0037310631     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50084     Document Type: Review

References (60)

1. Abuelo JG. Diagnosing vascular causes of renal failure. Ann Intern 1995;123:601-614.
2. Brady HR, Singer GG. Acute renal failure. Lancet 1998;346:1533-1540.
3. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-1460.
4. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. HEPATOLOGY 1996;23:164-176.
5. Cardenas A, Ginès P, Uriz J, Bessa X, Salmeron JM, Mas A, Ortega R, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. HEPATOLOGY 2001;34:671-676.
6. 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982;82:97-105.
7. Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liv Dis 1997;17:233-247.
8. Moore K. The hepatorenal syndrome. Clin Sci 1997;92:433-443.
9. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. HEPATOLOGY 2001;34:1242-1251.
10. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002;17:739-747.
11. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz Del Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
12. Moreau R, Asselah T, Condat B, De Kerguenec C, Pessione F, Bernard B, Poynard T, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90-94.
13. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni J-P, Ichaï P, Abergel A, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
14. Moreau R, Gaudin C, Hadengue A, Braillon A, Roulot D, Bacq Y, Lebrec D. Renal hemodynamic in patients with cirrhosis: relationship with ascites and liver failure. Nephron 1993,65:359-363.
15. Bosch J, Laine LA, Burroughs AK, Marcon N, Nevens F, Silvain C, Vinel JP. Baveno III consensus statements: treatment of the acute bleeding episode. In: de Franchis R, ed. Portal hypertension III. Proceedings of the third Baveno international consensus workshop on definitions, methodology and therapeutic strategies. London, Edinburgh, Malden, Carlton, Paris: Blackwell Science, 2001;168-169.
16. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995;108:1828-1834.
17. De Lédinghen V, Heresbach D, Fourdan O, Bernard P, Liebaert-Bories MP, Nousbaum JB, Gourlaouen A, et al. Anti-inflammatory drugs and varceal bleeding: a case-control study. Gut 1999;44:270-273.
18. American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
19. Fernandez J, Navasa M, Gomez J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. HEPATOLOGY 2002;35:140-148.
20. Navasa M, Follo A, Filella X, Jiménez W, Francitorra A, Planas R, Rimola A, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. HEPATOLOGY 1998;27:1227-1232.
21. Ginès A, Escorsell A, Ginès P, Salo J, Jimenez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
22. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
23. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-572.
24. FitzGerald GA, Patrono C. The COXIBS, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442.
25. Guevara M, Abecasis R, Jimenez W, Rios H, Terg R. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study [Abstract]. J Hepatol 2002;36(Suppl 1):203.
26. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994;331:1449-1450.
27. Guevara M, Fernandez-Esparach G, Ginès P, Calahorra B, Ozdogan O, Testuccia T, Montaya X, et al. Effect of radiocontrast agents on renal function in patients with cirrhosis and ascites [Abstract]. J Hepatol 2002;36(Suppl 1):202-203.
28. Salmeron J.M, Ruiz Del Arbol L, Ginès A, García-Pagan JC, Ginès P, Feu F, Claria J, et al. Renal effects of acute isosorbide-5-mononitrate adminitration in cirrhosis. HEPATOLOGY 1993;17:800-806.
29. Garcia-Pagan JC, Villanueva C, Vila MC, Albillos A, Genescà J, Ruiz Del Arbol L, Planas R, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers. Gastroenterology 2001;121:908-914.
30. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Capelli G, Raggi VC, et al. Effects of low-dose captopril on renal hemodynamics and function i patients with cirrhosis of the liver. Gastroenterology 1993;104:588-594.
31. Gonzalez-Abraldes J, Albillos A, Banarez R, Ruiz Del Arbol L, Moitinho E, Rodriguez C, Gonzalez M, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-388.
32. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-395.
33. Montseny JJ, Meyrier A, Kleinknecht D, Callard P. The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. Medicine 1995;74:63-73.
34. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998;54:650-671.
35. Cadranel JF, Soltani N, Guettier C, Fleury D, Poux JM, Hillion D, Vanhille P, et al. Macroscopic hematuria with glomerular bleeding: a peculiar form of acute renal failure in cirrhotic patients [Abstract]. J Hepatol 2002;36(Suppl 1):203.
36. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effect of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-916.
37. Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Assous M, Sicot C. Clinical, hemodynamic and metabolic characteristics and ICU outcome of septic shock in patients with cirrhosis. Crit Care Med 1992;20:746-750.
38. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing othotopic liver transplantation. HEPATOLOGY 2002;35:1179-1185.
39. Couser WG. Glomerulonephritis. Lancet 1999;353:1509-1515.
40. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, RoudotThoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. HEPATOLOGY 2002;36:374-380.
41. Jouët P, Meyrier A, Mal F, Callard P, Guettier C, Stordeur D, Trinchet JC, et al. Transjugular renal biopsy in the treatment of patients with cirrhosis and renal abnormalities. HEPATOLOGY 1996;24:1143-1147.
42. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trial Group. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet 2000;356:2139-2143.
43. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
44. Bernard GR, Vincent JL, Laterre PF, La-Rosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
45. Plessier A, Denninger MH, Durand F, Francoz C, Francque S, Lebrec D, Valla D, et al. Marked decreases in protein C and antithrombin III activities in patients with cirrhosis and severe sepsis [Abstract]. J Hepatol 2002;36(Suppl 1):178.
46. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. HEPATOLOGY 1999;29:1690-1697.
47. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-286.
48. Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367.
49. Allgren RL, Marbury TC, Rahman N, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, et al. Anaritide in acute tubular necrosis. N Engl J Med 1997;336:828-834.
50. Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal failure Study Group. Am J Kidney Dis 2000;36:767-774.
51. Shilliday IR, Quinn KJ, Allison MEM. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant 1997;12:2592-2596.
52. Phu NH, Hien TT, Mai NT, Chau TT, Chuong LV, Loc PP, Winearls C, et al. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med 2002;347:895-902.
53. Vanholder R, Van Biesen W, Lameire N. What is the renal replacement method of first choice for intensive care patients? J Am Soc Nephrol 2001;12:S40-S43.
54. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MTA, Farkas A, Kaplan RM, et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001;60:1154-1163.
55. Vanholder R, Lameire N. Does biocompatibility of dialysis membranes affect recovery of renal function and survival? Lancet 1999;354:1316-1318.
56. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26-30.
57. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305-310.
58. Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation. Part II. Liver Transpl 2002;8:193-211.
59. Safirstein RS, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents-a new use for an old drug. N Engl J Med 2000;343:210-212.
60. Tepel M, Van Der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.